Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis

Background: Safinamide is a novel α-aminoamide with dopaminergic and non-dopaminergic properties developed as adjunctive therapy for patients with PD. Results from a 24-month double-blind controlled study suggested that as add-on to levodopa (and other PD medications) the benefits of safinamide on d...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Parkinsons Dis
Asıl Yazarlar: Cattaneo, Carlo, Ferla, R. La, Bonizzoni, Erminio, Sardina, Marco
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: IOS Press 2015
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4923744/
https://ncbi.nlm.nih.gov/pubmed/26406127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-150569
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller